CHARLOTTE, North Carolina—AOM Infusion (AOM), a specialty infusion provider focused on intravenous immunoglobulin (“IVIG”), chronic inflammatory (CID) and specialty infusion therapy, announced that Keyur Mehta has been named chief executive officer. Christopher York will continue in his position as chairman of AOM.
“There is a significant opportunity for AOM to further expand our services into new markets and therapies as patients increasingly opt for at-home and ambulatory treatment options,” said Mehta. “The entire team at AOM has done a remarkable job positioning the Company for success. I am energized and excited about our Company’s future and look forward to building on AOM’s exceptional track record.”
Mehta brings more than 25 years of experience in health care, primarily within the alternate site infusion and specialty pharma industries. He has been an entrepreneur in the infusion pharmacy and health care consulting spaces and has held executive roles in both public and private companies, including DaVita, Option Care Health, BioScrip and InfuScience. His expertise spans multi-site operations, strategy, business development and clinical services. Mr. Mehta holds a bachelor’s degree in biochemistry from New York University, a bachelor’s degree in pharmacy from St. John’s University and an MBA from Virginia Tech University.
Mehta joined AOM in 2022 as chief operating officer and quickly forged a strong partnership with the company’s executive leadership team as well as the health care investment team at Ridgemont Equity Partners, which acquired AOM last year. Under Mehta’s leadership, AOM has increased its payer network and expanded its therapeutic offering while continuing its growth as a leading provider of IVIG infusion therapy.
“Keyur is an experienced specialty infusion executive and we have been impressed by his operational and team-building capabilities,” said Petri Lindberg, principal at Ridgemont Equity Partners. “We look forward to continuing to execute AOM’s strategic business plan under Keyur’s leadership.”
